All of us “beat the drum” when it comes to vaccines. We promote them, administer them, and depend on them to assist in preventing infections. But what about residents with a schizophrenia diagnosis who are receiving antipsychotic medications? A recent study published in Lancet Psychiatry identified that these residents are at higher risk for severe respiratory infections. The link between antipsychotics and infection risks in senior care is an important topic that warrants attention.

As if a schizophrenia diagnosis isn’t challenging enough, the treatments used to manage symptoms may increase the risk of infection. Residents living with mental health disorders treated with antipsychotic medications can exhibit anti-social behaviors and refuse care. Are your residents prescribed antipsychotics and refusing vaccines being educated about the risk/benefit ratio? Maybe a few statistics would help. Hospitalization risk related to COVID-19 was highest among those exposed to antipsychotics, and the risks for other respiratory infection-related hospitalizations were also significantly higher.

It might be time to examine what is happening and why. Pneumococcal vaccination, which is recommended for most residents, becomes even more critical for those living with schizophrenia and receiving antipsychotic medications. As study author Vardan Nersesjan, MD, from Copenhagen University Hospital, noted: “It seems reasonable to initiate infection countermeasures such as pneumococcal vaccination in people older than 40 years with schizophrenia spectrum disorders who commence or are treated with antipsychotics.” This could be an excellent PIP (Performance Improvement Project) for your QAPI committee and mental health provider.

Stay well and stay informed!